| [1] Sharma M,Machuy N,Böhme L,et al. HIF-1α is involved in mediating apoptosis resistance to Chlamydia trachomatis -infected cells. Cell Microbiol,2011,13(10):1573-1585.
[2] Choroszy-Król I C,Frej-Madrzak M,Jama-Kmiecik A,et al. Characteristics of the Chlamydia trachomatis species-immunopathology and infections. Adv Clin Exp Med,2012,21(6):799-808.
[3] Grayston J T,Belland R J,Byrne G I,et al. Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested. Pathog Dis,2015,73(1):1-9.
[4] Bachmann N L,Polkinghorne A,Timms P. Chlamydia genomics:providing novel insights into chlamydial biology. Trends Microbiol,2014,22(8):464-472.
[5] Schijns V E,Lavelle E C. Trends in vaccine adjuvants. Expert Rev Vaccines,2011,10(4):539-550.
[6] Helgeby A,Robson N C,Donachie A M,et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol,2006,176(6):3697-3706.
[7] Igietseme J U,Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun,2000,68(12):6798-6806.
[8] Zhang Dong-Ji,Yang X,Shen C,et al. Priming with Chlamydia trachomatis major outer membrane protei (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immuneresponses. Infect Immun,2000,68(6):3074-3078.
[9] Zhao J,Bagchi S,Wang C R. Type II natural killer T cells foster the antitumor activity of CpG-oligodeoxynucleotides. Oncoimmunology,2014,3(5):1-2.
[10] Cheng C,Pal S,Bettahi I,et al. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membraneprotein in a nonhuman primate model. Vaccine,2011,29(18):3456-3464.
[11] Meoni E,Faenzi E,Frigimelica E,et al. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun,2009,77(9):4168-4176.
[12] Vasilevsky S,Greub G,Nardelli-Haefliger D,et al. Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research. Clin Microbiol Rev,2014,27(2):346-370.
[13] Cong Y,Jupelli M,Guentzel M N,et al. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhancesprotective immunity against genital Chlamydia muridarum infection. Vaccine,2007,25(19):3773-3780.
[14] Aguilar J C,Rodríguez E G. Vaccine adjuvants revisited. Vaccine,2007,25(19):3752-3762.
[15] 周红莉,郭丽,王健伟,等. 粘膜免疫佐剂研究进展. 中国生物工程杂志,2006,26(3):83-88. Zhou H L,Guo L,Wang J W,et al. Progress in mucosal adjuvants. China Biotechnology,2006,26(3):83-88.
[16] 齐蔓莉,王敬,刘原君,等. 白细胞介素2基因佐剂对沙眼衣原体E型DNA疫苗的免疫增效作用. 中华皮肤科杂志,2012,45(5):322-324. Qi M L,Wang J,Liu Y J,et al. Immune enhancing effects of interleukin 2 genetic adjuvant on DNA vaccine against Chlamydia trachomatis serovar E. Chinese Journal of Dermatology,2012,45(5):322-324.
[17] 谢长青,吴移谋,曾焱华,等. 肺炎嗜衣原体MOMP和人IL-2融合基因DNA疫苗的免疫原性研究. 中国人兽共患病学报,2009,25(9):837-841. Xie C Q,Wu Y M,Zeng Y H,et al. Immunogenicity of the DNA vaccine with monogene and fusion gene of the major outer membrane protein in Chlamydia pneumoniae and human IL-2. Chinese Journal of Zoonoses,2009,25(9):837-841.
[18] 赵占中,薛飞群. DNA疫苗的免疫佐剂. 中国动物传染病学报,2010,18(2):79-86. Zhao Z Z,Xue F Q. The adjuvants for DNA vaccines. Chinese Journal of Veterinary Parasitology,2010,18(2):79-86.
[19] Zhang Y,Liang S,Li X,et al. Mutual enhancement of IL-2 and IL-7 on DNA vaccine immunogenicity mainly involves regulations on their receptor expression and receptor-expressing lymphocyte generation. Vaccine,2015,33(30):3480-3487.
[20] Staats H F,Bradney C P,Gwinn W M,et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol,2001,167(9):5386-5394.
[21] 孟庆峰,徐展,王伟利. 活载体疫苗的研究进展. 黑龙江畜牧兽医,2013,19:28-31. Meng Q F,Xu Z,Wang W L. Research progress of the live vector vaccine. Heilongjiang Animal Science and Veterinary Medicine,2013,19:28-31.
[22] Zhou J,Qiu C,Cao X A,et al. Construction and immunogenicity of recombinant adenovirus expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci in chicks. Vaccine,2007,25(34):6367-6372.
[23] He Q,Martinez-Sobrido L,Eko F O,et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology,2007,122(1):28-37.
[24] Penttilä T,Tammiruusu A,Liljeström P,et al. DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. Vaccine,2004,22(25-26):3386-3394.
[25] 靳小攀,季守平. 细菌菌影在DNA疫苗研究中的作用. 中国生物工程杂志,2010,30(7):92-96. Jin X P,Ji S P. Research in bacterial ghost as DNA vaccine delivery system. China Biotechnology,2010,30(7):92-96.
[26] Eko F O,Lubitz W,McMillan L,et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine,2003,21(15):1694-1703.
[27] Eko F O,He Q,Brown T,et al. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol,2004,173(5):3375-3382.
[28] Macmillan L,Ifere G O,He Q,et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol,2007,49(1):46-55.
[29] 潘青. 猪流产衣原体Pmp18N-rVCG疫苗的构建、小鼠免疫评价和机制研究. 北京:中国农业大学,2015. Pan Q. Construction and comparative evaluation of Chlamydia abortus subunit candidate vaccine rVCG-Pmpl8N in a mouse model and immune mechanism of DC pulsed with Pmpl8N. Beijing:China Agricultural University,2015.
[30] Sivakumar S M,Safhi M M,Kannadasan M,et al. Vaccine adjuvants-current status and prospects on controlled release adjuvancity. Saudi Pharm J,2011,19(4):197-206.
[31] Hansen J,Jensen K T,Follmann F,et al. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis,2008,198(5):758-767.
[32] Yu H,Karunakaran K P,Jiang X,et al. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun,2012,80(4):1510-1518.
[33] Stary G,Olive A,Radovic-Moreno A F,et al. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science,2015,348(6241):8205.
[34] Dixit S,Singh S R,Yilma A N,et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. Nanomedicine,2014,10(6):1311-1321.
[35] Fairley S J,Singh S R,Yilma A N,et al. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper1cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomedicine,2013,8(1):2085-2099. |
